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LIST OF ABBREVIATIONS 
AIRg Acute phase of insulin response to hyperglycemia 
BMI Body mass index 
DI Disposition index 
DPP-IV Dipeptidyl peptidase - 4 
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GIR Glucose infusion rate 
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Lp(a) Lipoprotein (a) 
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RYGB Roux en Y gastric bypass 
T2DM Type 2 diabetes mellitus 
TG Triglyceride 
VLDL Very low density lipoprotein 
WC Waist circumference 
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1. INTRODUCTION 
1.1. Obesity 
Obesity is characterized by an excessive fat accumulation that may harm health. It is defined 
by a body mass index (BMI) greater than or equal to 30 kg/m2. Prevalence of obesity is 
increasing quickly and becomes a major challenge in the world. WHO estimated about 10 % 
of men and 14 % of women having obesity (BMI ≥30 kg/m2) in 2008 [1]. Obesity is the major 
risk factor of many comorbidities such as type 2 diabetes mellitus (T2DM), dyslipidemia, 
hypertension, heart diseases, non-alcoholic fatty liver disease, cancers, sleep apnea, bone-joint 
diseases, dementia, psychosocial dysfunctions [2]. The classification of obesity in adults is 
determined by BMI that is calculated by weight in kilograms divided by height in meters 
squared [weight (kg) / height (m2)] (Table 1). 
Table 1: Classification of obesity in adults by BMI (2000, WHO, Geneva) 
Classification of obesity BMI Risk of comorbidities 
Underweight < 18.05 
Low (but risk of other 
clinical problems increased) 
Normal range 18.05-24.99 Average 
Overweight ≥ 25.00  
Overweight 25.00-29.99 Increased 
Obese class I 30.00-34.99 Moderate 
Obese class II 35.00-39.99 Severe 
Obese class III ≥ 40 Very severe 
  
1.2. Type 2 diabetes mellitus 
Diabetes mellitus is a metabolic disorder characterized by elevation of plasma glucose which 
may be the result of a variety of pathologies. The majority (> 90 %) of patients with diabetes 
suffer from diabetes type 2. In these patients, chronic hyperglycaemia often associated with 
disturbances of carbohydrate, fat and protein metabolism result from defects of insulin 
secretion, insulin action or both. It was accounted that more than 371 million people in the 
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world had diabetes in 2012 and half of this number was not diagnosed. It is estimated that the 
number of diabetic patients will be over 552 million by 2030 and will increase in every 
country in the world [3]. The increase in T2DM prevalence is closely related to an increase in 
obesity. The prevalence of T2DM in obese patients is much higher than that in normal weight 
patients. The physiological abnormalities of glucose metabolism in T2DM commonly include 
insulin resistance, β-cell defects and abnormalities of insulin secretion such as first-phase and 
second-phase secretion [4]. Insulin resistance can be defined as the inability of insulin to fully 
perform its normal biological functions at circulating concentrations that are well effective in 
healthy subjects. Obesity leads to insulin resistance that precedes and predicts T2DM. Insulin 
resistance manifests itself not only in impaired inhibition of hepatic glucose production but 
also in decreased peripheral uptake of glucose. In healthy subjects hepatic glucose production 
is suppressed almost completely after a meal by the increase in plasma insulin and glucose 
concentrations. This complete suppression of hepatic glucose production helps to keep 
postprandial glucose concentration in the normal range. The impaired suppression of hepatic 
glucose production resulting from insulin resistance is one factor leading to the increase of 
postprandial blood glucose in T2DM. Evidence from many studies indicate that in insulin 
resistance insulin also fails to inhibit very low density lipoprotein (VLDL) production in the 
liver which contributes to the increase in serum triglyceride (TG) levels [5]. After a meal, 
approximately one-third of glucose is taken up by skeletal muscle. The impaired effect of 
insulin on glucose uptake in skeletal muscle and adipose tissues in T2DM subjects has been 
established in many studies. This further contributes to postprandial hyperglycaemia [6]. 
There have been many indexes to assess the insulin resistance such as oral glucose tolerance, 
the homeostasis model assessment of insulin resistance (HOMA-IR), the insulin sensitivity 
index (ISI) calculated from the fasting plasma insulin and glucose. However, the index of 
metabolised glucose during an euglycemic clamp (EGC) is considered gold standard to 
quantify insulin resistance [7].  
In experiments using an acute square wave of hyperglycaemia such as in hyperglycaemic 
clamp (HGC) experiments but also in in-vitro experiments insulin response occurs in two 
phases. The acute phase of insulin response to hyperglycemia (AIRg) occurs immediately and 
lasts for approximately ten minutes. The second-phase is followed by the gradual increase of 
insulin secretion and continues as long as hyperglycemia persists (Figure 1). The AIRg relates 
to the exocytosis of insulin containing granules located next to the plasma membrane of β 
cells. The exocytosis is a very complex mechanism in which intracellular calcium 
concentration plays a major role. The second phase of insulin secretion relates to the synthesis 
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of new insulin molecules and the movement of insulin storage granules toward the plasma  
membrane [8]. For a long time, it was unclear whether ß-cell dysfunction is the underlying 
pathogenesis of T2DM. Recently, it is believed that impaired ß-cell function and insulin 
resistance occurs in parallel. As the development of T2DM is considered to pass through five 
stages, the decrease of ß-cell function can be founded at stage 2. The deterioration in ß-cell 
function happens further, and as a result, postprandial and fasting glucose concentrations 
reach levels for diabetic diagnosis at the stage 5. The HGC is considered to be the gold 
standard for assessing AIRg. 
 
 
 
 
Figure 1: Biphasic insulin secretion in vitro from high glucose perfused pancreas, 
reproduced from Jones PM et al. [9]. 
 
1.3. Obesity and type 2 diabetes mellitus with bariatric surgery 
Treatment of T2DM and obesity is challenging and often expensive. Although pharmaceutical 
treatment of T2DM can improve the prognosis of the affected patients, the long-term 
treatment of the underlying obesity is often problematic for both patients and care-takers. 
Over the last 10 years bariatric surgery has been used widely for the treatment of morbidly 
obese patients because long-term control of obesity is more substantial than with life-style 
interventions or drug therapy. Bariatric surgery can be classified into three main types, purely 
restrictive procedures including laparoscopic adjustable gastric banding (LAGB) and 
laparoscopic sleeve gastrectomy (LSG), malabsorptive techniques such as jejunoileal bypass, 
and the combined restrictive and malabsorptive techniques presented by Roux-en-Y gastric 
bypass (RYGB). Besides the effects on weight control that is the principle and classic target 
of bariatric surgery, most of recent studies have shown that bariatric surgery can induce a 
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substantial rate of T2DM remission or an improvement in impaired glucose tolerance, not 
specific for the types of intervention. In a systematic review and meta-analysis on 136 full 
studies, Buchwald H et al. described complete remission of T2DM in over 75 % of patients 
after bariatric surgery [10]. Although the remission rate of T2DM is impressive following 
bariatric surgery, it remains unclear whether this results from caloric restriction and weight 
loss or other additional factors. 
1.4. Caloric restriction, weight loss, and other factors mediating the improvement in 
type 2 diabetes mellitus after bariatric surgery. 
1.4.1. Caloric restriction and weight loss 
Caloric restriction starts immediately after surgery. Improvement in glucose metabolism can 
be detected soon after, well before weight reduction occurs. It is therefore plausible that 
caloric restriction and not weight loss alone mediates the antidiabetic effect. It is known for a 
long time that the modification of macro-nutrients and of energy amount can affect glucose 
metabolism [11]. The weight loss-independent effect of caloric restriction on metabolism was 
also described in the study of Kelley DE et al. when the author tested the role of caloric 
restriction in seven obese patients with T2DM [12]. Many study groups have highlighted the 
role of caloric restriction in the improvement in glucose metabolism after both restrictive and 
malabsorptive procedures [13, 14]. 
Obesity is a major risk factor of insulin resistance and T2DM. Risk of T2DM is strongly 
associated with the duration and the degree of obesity. A large body of evidence shows that 
there is the strong correlation between obesity and T2DM, and any form of weight loss results 
in the improvement in glucose metabolism [15, 16]. In an evidence report of NIH conducted 
in 1998, weight loss was recommended to lower high blood glucose levels in overweight and 
obese patients with T2DM. A modest weight loss, even as low as 10 % of body weight, could 
lead to a significant improvement in insulin resistance and T2DM [17, 18]. Even little weight 
gain, on the other hand, can cause hyperinsulinemia and insulin resistance [19]. LAGB and 
LSG, the purely restrictive procedures, are thought to improve glucose homeostasis mostly by 
weight loss and restricted food intake. In a study including 143 obese patients undergoing 
LAGB, Pontiroli AE et al. showed that there was a significant improvement in glucose 
metabolism and this improvement was proportional to the degree of weight loss [20]. Hady 
HR et al. studied the outcomes after LSG on 100 obese patients and described that weight loss 
after LSG is the main mediator of improved glucose metabolism [21]. Many authors also 
highlight the correlation between weight loss and the T2DM remission after bariatric surgery 
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with malabsorptive techniques. The significant correlation between the T2DM remission and 
excess weight loss was documented in the investigation of Sugerman HJ et al. on a cohort of 
1025 obese patients (15 % had T2DM) at 1, 5 and 7 years after gastric bypass [22]. Although 
weight loss without doubt has an important role in the improvement in T2DM after bariatric 
surgery, a number of studies indicated that there may be other additional factors. 
1.4.2. Additional factors 
Many current studies show that the antidiabetic effect is present very early after bariatric 
surgery before any significant weight loss occurs and that it is not specific for any type of 
intervention. A strong and significant improvement in glucose metabolism just 3 days after 
LSG was described by Rizzello et al. in a study of 17 T2DM patients with obesity [23]. In the 
study of Schauer PR et al. on 240 T2DM patients who underwent RYGB and were treated 
with medications and/or insulin before surgery, 30 % of patients could stop diabetic treatment 
immediately after discharge from the hospital before any significant weight loss [24]. In a 
study by Umeda LM et al. conducted in 10 obese T2DM patients it was shown that there was 
a significant improvement in HOMA-IR index 7 days after RYGB without significant weight 
loss [25]. Many trials document that the rate of diabetic remission after bariatric surgery in 
less obese patients (BMI < 35 kg/m2) is similar to that in morbidly obese patients [26] and 
therefore  the term “bariatric surgery” is currently being replaced by the term “metabolic 
surgery” when this form of therapy is used to treat diabetes in non-morbidly obese patients. 
The non-significant association between the rate of T2DM remission and degree of weight 
loss after bariatric surgery was also described in many studies [23, 27]. The stronger 
improvement in glucose metabolism after bariatric surgery than after the marked weight loss 
from other non-surgical interventions indicated weight loss-independent antidiabetic effects of 
bariatric surgery. Laferrère B et al. designed a study to compare the effects of weight loss by 
RYGB versus calorie-restricted diet on glucose metabolism in T2DM patients. This study 
showed that although weight loss was equivalent in both groups, the improvement on 
postprandial blood glucose was markedly stronger in the RYGB group [28]. All this indicates 
that diabetic remission after bariatric surgery may be mediated by additional factors and 
independent to weight loss. 
 
Many studies indicate that hormonal factors, such as ghrelin and incretin hormones, play an 
important role in mediating this effect.  
Ghrelin: Ghrelin is a gastro-intestinal hormone secreted mainly from gastric fundus. While 
Ghrelin is secreted in the fasting state and suppressed after a meal, it stimulates appetite and 
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food intake, inhibits pancreatic insulin secretion, increases hepatic glucogenesis, and leads to 
hyperglycemia [29]. Nearly total resection of the gastric fundus in LSG leads to low serum 
ghrelin levels which mediate anorexic and antidiabetic effects. However, the effect of RYGB 
on ghrelin concentration is heterogeneous, which may relate to the manipulation of the vagal 
nerve during the operation [30]. Obesity and insulin resistance are usually accompanied by 
low ghrelin levels, which indicates that a lower ghrelin concentration is not enough to resolve 
obesity and diabetes [31]. Although low levels of ghrelin may contribute to diabetes remission 
after bariatric surgery, it is not the main component.
 
Incretins: In 1964, two independent research groups (Mclntyre N and Elrick H) 
simultaneously showed that the insulin response of pancreatic ß-cells to oral glucose 
administration was markedly stronger than that to intravenous glucose administration. This 
great difference of insulin response was called ‘‘incretin effect’’ [32, 33] (Figure 2).  
 
 
 
Figure 2: Insulin response to oral and intravenous administration of glucose [32] 
 
Incretin hormones, such as glucagon-like peptide-1 (GLP-1) and glucose-dependent 
insulinotropic polypeptide (GIP), are gut peptides that induce a series of physiological 
responses, especially in glucose metabolism, after a meal. GLP-1, being produced mainly in L 
cells at the distal small gut and colon, plays the major role in the incretin effect. GLP-1 is 
formed from proglucagon via processing that requires prohormone convertase-1. Inactive 
GLP-1(1-37) is processed to bioactive GLP-1(7-36) that is quickly degraded by dipeptidyl 
peptidase – 4 to GLP-1(9-36) after secreting from the L cells [34]. GLP-1 stimulates the 
glucose-dependent insulin release via GLP-1 receptor binding, improves both fasting and 
postprandial blood glucose, retards gastric emptying, inhibits glucagon secretion of α cells, 
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and induces anorectic effects. GLP-1 also affects the proliferation and the apoptosis of islet ß 
cells. GIP is released essentially from duodenal K cells, regulates predominately postprandial 
blood glucose, and has only slight influence on gastric emptying and little anorectic effect 
(Figure 3). Like GLP-1, bioactive GIP(1-42) is converted to inactive GIP(3-42) by dipeptidyl 
peptidase - 4 just minutes following the secretion from K cells [35]. Analogues of GLP-1 and 
GIP as well as dipeptidyl peptidase - 4 inhibitors are used today as a new generation of 
antidiabetic medications. Under the effect of the incretin hormones that are secreted after the 
meal, the insulin response after an oral glucose load is greater than that after an isoglycemic 
intravenous glucose infusion [34]. 
 
                                                                        
                                                 
                                                    
 
                                                                                   
 
 
 
 
 
                                                                                                                                                                                                    
 
 
Figure 3: Main effects of incretin hormones on glucose metabolism 
 
In non-diabetic subjects postprandial glucose concentrations are kept at a normal level   
independent of the amount of glucose in the meal. This is largely related to the incretin effect 
[36]. Although T2DM patients are characterized by a decreased incretin effect, the degree of 
GLP-1 
GIP 
Insulin secretion 
Glucose clearance 
Glucagon secretion 
 
Gastric emptying 
Blood glucose 
9 
 
impairment is not constant in various studies, and may relate to duration and severity of 
diabetes [37]. In individuals with T2DM, postprandial GLP-1 concentrations seem to be 
decreased, but the effect of exogenous GLP-1 on insulin response persists. Contrary to GLP-
1, GIP levels seem to be normal but the effect of GIP on insulin response decreases [38, 39]. 
An improved IE may play a major role in mediating the antidiabetic effect of bariatric 
surgery. LSG delays the delivery of ingested foods to the distal portions of the gut and this 
may lead to an increased stimulation of L-cells and K-cells to release incretin hormones. Two 
study groups, Valderas et al. and Romero et al., described that postprandial GLP-1 and GIP 
levels increase significantly after LSG in obese patients [40, 41]. In contrast to LSG, RYGB 
leads to a status where food bypasses the duodenum. This could theoretically lead to low 
levels of incretin hormones after surgery. However, the level of incretin hormones and the 
incretin effect improve significantly after RYGB in many studies. Näslund E et al. studied the 
response of incretin hormones to the meal in obese patients after jejunoileal bypass. The 
authors documented that the GLP-1 and GIP response was normalized 9 months after 
operation. The authors concluded that the improvement in glucose metabolism might result 
from the increase of incretin hormones [42]. In a study of Laferrère B et al., the authors 
showed that the greater secretion of incretin hormones and the improved incretin effect early 
after GBP may be responsible for antidiabetic effects after surgery [28]. 
The improvement in glucose metabolism after bariatric surgery has obtained a growing 
attention in the clinical and scientific community. The underlying mediated mechanisms, 
however, are still unclear. The role of caloric restriction and weight loss in antidiabetic effects 
after bariatric surgery is still controversial. 
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2. AIMS OF STUDY 
- To evaluate the effect of caloric restriction and weight loss on glucose metabolism and 
other clinical outcomes. 
- To determine the mechanisms underlying the improved glucose metabolism following 
caloric restriction and weight loss, focussing on: 
+ Incretin effect. 
+ Intravenous-glucose stimulated insulin response 
+ Insulin resistance. 
The results of this study will help to explain the role of caloric restriction and weight loss in 
the observed improvement of glucose metabolism after bariatric surgery. 
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3. SUBJECTS AND METHODS 
3.1. Approval procedure and informed consent 
The study is part of a larger project evaluating “Glucose metabolism after sleeve gastrectomy 
in obese type 2 diabetic patients”. This study was approved by the Ethics Committee of the 
Medical Faculty of the Ludwig-Maximilians University, Munich, Germany under project 
number 120-09. The study was funded by German Research Foundation (DFG) under 
approved number DFG GZ: BR 151/5-1. Our study is a randomized, single centre, un-
controlled, prospective trial. All subjects gave written consent after they had received the 
information about the study and had carefully read the subjects information. 
3.2. Subjects 
Twelve obese patients with T2DM participated in a calorie-restricted intervention of 3 months 
that is equivalent to the diet of patients during the first 3 months after laparoscopic sleeve 
gastrectomy. Glucose metabolism, potential mechanisms mediating the of improved glucose 
metabolism, lipid metabolism, and other clinical outcomes are assessed before and after 
caloric restriction. 
3.2.1. Inclusion criteria 
- Type 2-diabetes mellitus 
- Obesity ≥ grade II (BMI ≥ 35 kg/m²) 
- Age 18-65 years 
- Signed informed consent 
3.2.2. Exclusion criteria 
- Type 2-diabetes duration of more than 10 years 
- Uncontrolled type 2-diabetes: Fasting glucose > 200 mg/dl, or HbA1c > 10 % 
- Patients with intensive insulin therapy  
- Therapy with thiazolidindions within the last 3 months 
- Type 1-diabetes mellitus 
- Alcohol abuse (woman > 70 g/week, man > 140 g/week), nicotine abuse or drug abuse 
- Hepatic diseases (except non-alcoholic fatty liver disease) 
- Renal insufficiency (glomerular filtration rate < 50 ml/min/1.73) 
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- Cardiac failure > NYHA I 
- Uncontrolled thyroid diseases or other endocrinological diseases 
- Pregnancy 
- Acute or chronic inflammation 
- Malignant diseases 
- Anemia (Hemoglobin < 12 mg/dl for woman, < 14 mg/dl for man) 
- Using anticoagulation medication under bioactive period, except Aspirin 100mg 
3.3. Study procedure and methods 
The whole study included a screening visit, 3 visits (visit 1, visit 2, and visit 3), and a calorie-
restricted intervention (Figure 4). The oral anti-diabetic medications had to be withdrawn 7 
days before every visit. GLP-1 analogues and DPP-IV inhibitor were withdrawn at least 4 
weeks before visit 1 and were not taken again during the study. The therapy with long-acting 
insulin analogues was withdrawn the latest one day before every visit. We regularly contacted 
the subjects after withdrawing of any anti-diabetic medications to make sure that blood 
glucose was not over 200 mg/dl. 
3.3.1. Screening 
Potential candidates were recruited from a number of different sources: announcements in 
public media, flyers and posters, word of mouth. We also recruited potential candidates from 
the outpatient metabolic clinic of Medical Department 2, Großhadern. First, we talked with 
potential candidates by telephone to explain the study, to know the disease history, and to 
check the inclusion and exclusion criteria. Next, potential candidates came for the official 
screening visit at the Clinical Research Unit in our hospital, where we described again the 
study in more detail, handed the ‘‘patients information documents’’ over to the subjects, 
asked about the disease history, and examined the patient clinically after she or he had signed 
the informed consent form. Blood and urine samples were taken for some parameters. If all 
inclusion criteria were fulfilled and no exclusion criteria present the subject was included in 
the study. At the screening visit, the subject also participated in a dietary consultation to 
ensure full compliance with the calorie-restricted intervention during the study. Plan for visit 
1 would be done.  
 
 
13 
 
The following criteria were used to diagnose T2DM:  
- Fasting plasma glucose ≥ 7.0 mmol/l (126 mg/dl), or 
- 2-h plasma glucose ≥ 11.1 mmol/l (200 mg/dl), or 
- HbA1c ≥ 6.5 %, or 
- Treatment with any anti-diabetic medication 
 
 
 
 
 
 
 
 
                       
 
 
 
 
 
 
 
 
 
Figure 4: Timeline of study 
 
3.3.2. Visit 1 
Visit 1 was scheduled approximately 2 weeks after the screening visit and before caloric 
restriction started. During the week before visit 1, the subject had to comply with a diet 
consisting of 18 “Broteinheiten” (corresponding to 216 gr of carbohydrates/day) with 
approximately 15 % protein, 30 % fat, and 55 % carbohydrates (dietary protocol I) (Figure 7). 
The physical activity was also kept stable to keep body weight stable (± 2 kg). Visit 1 lasted 3 
days (day 1, day 2 and day 3) and supplied the basal data (before caloric restriction). 
 
Visit 2 Visit 3 Visit 1 
Screening 
 
Calorie-restricted intervention 
In hospital 
0-700 kcal 1400 kcal 
At home 
-4 weeks 
-2 weeks 
Day 0 
Day 10 12 weeks 
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Day 1: hyperglycemic clamp with test meal 
In the HGC with test meal, we raised the plasma glucose concentration to 100mg/dl over the 
fasting concentration and maintained it stable for 6 hours. The glucose supply came from an 
intravenous glucose infusion for the first 120 minutes and from intravenous glucose infusion 
plus the oral meal for the last 240 minutes (Figure 5). The subjects were admitted to the 
clinical research unit in our hospital, between 7:30 and 8:00a.m after an 8 hour fast. Body 
weight, height, waist circumstance, blood pressure, and pulse were measured. An intravenous 
catheter was placed in each forearm, one for blood withdrawal and another for glucose 
infusion. The forearm used for blood-withdrawal was warmed continuously during the clamp 
with a heating lamp to arterialize the venous blood. One blood sample for lipid profile and 
four blood samples for the fasting parameters of blood glucose, insulin, and C-peptide at 4 
separated time-points were withdrawn after the subject had rested in bed for one hour. 
Following this (considered as time-point 0 minute), a 20 % glucose bolus (dose see below) 
was given within 1 minute and followed by a continuous infusion of 20 % glucose solution to 
raise and maintain the blood glucose concentration 100 mg/dl over fasting blood glucose.  
Glucose bolus dose (mg) = Body weight (kg) x 100(mg/dl) x 1,5 
At 120 minutes, the subject received a 324 kcal-semisolid meal containing 20 % protein, 40 % 
lipid and 40 % carbohydrate plus 100mg 13C-Sodium Acetate within 5 minutes. To maintain a 
stable blood glucose at 100 mg/dl over fasting blood glucose during the clamp, the infusion 
rate of 20 % glucose solution was modified every 5 minutes based on results of arterialized 
blood glucose. Blood samples for insulin and C-peptide parameters were withdrawn at time-
points of 2, 4, 6, 8, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 125, 130, 135, 140, 145, 
150, 160, 170, 180, 195, 210, 225, 240, 255, 270, 285, 300, 315, 330, 345, 360 minutes. The 
assessment for full consciousness, hunger, nausea, and satiety was done by the visual 
analogue scales (VAS) at the time-points of 0, 105, 120, 135, 150, 165, 180, 210, 240, 300, 
and 360 minutes. The estimation of gastric emptying time was performed at the time-points of 
120 (before the meal test), 135, 150, 165, 180, 195, 210, 225, 240, 270, 300, 330, and 360 
minutes by 13 inflated breathing bags. The measurement of 13C enrichment in breath CO2 was 
done by Isotope Ratio Mass Spectrometry (IRMS). The hyperglycaemic clamp can 
conceptually be divided into 2 stages. The first stage during which glucose supply comes only 
from the intravenous glucose infusion lasted from 0 to 120 minutes. The main purpose of this 
first stage was to assess the ß cell response including first-phase and second-phase response to 
an intravenous glucose infusion [7]. The second phase lasted from 120 to 360 minutes and 
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started with the test meal. The glucose supply for the body during the second stage comes 
from intravenous glucose infusion plus the oral meal. The goal of this second phase is to 
assess the incretin effect. During and at the end of the clamp, urine was collected to determine 
the urine glucose excretion. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  -60       0                                   120                                                                     360 minute 
 
 
 
Blood samples for: Blood glucose, insulin, and C-peptide 
VAS and Gastric emptying time test 
Figure 5: Process of hyperglycaemic clamp with the test meal 
 
 
Day 2: Euglycemic clamp     
The EGC was started after an 8 hour fast and lasted for 3.5 hours. One intravenous catheter 
was again placed in each forearm, one for blood drawing and one for infusing both insulin and 
20 % glucose solution. Again the forearm used for blood sampling was warmed as described 
above to arterialize the blood. After resting in the bed for one hour, the patient received an 
intravenous insulin infusion with the fixed infusion rate of 1,5 IU/kg/min. The goal of the 
Go 
+100 
mg/dl 
IV bolus 
Meal 
IV glucose IV glucose + meal glucose 
Insulin response ? Insulin response ? 
Incretin effect ? 
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insulin infusion was to lower the blood glucose to 90 mg/dl. Insulin infusion with the fixed 
rate was kept until the end of the clamp. Blood glucose was tested every 5 minutes, and 20 % 
glucose infusion rate was modified to maintain blood glucose at 90 mg/dl during clamp. 
Blood samples for insulin and C-peptide assays were regularly withdrawn at time-points of -
30, 0, 20, 40, 60, 80, 100, 120, 130, 140, 150, 160, 170, 180 minutes (Figure 6).  
             
 
 
 
                                                                       
 
 
 
 
 
 
 
 
 
 
Blood samples for: Blood glucose, insulin, and C-peptide 
Figure 6: Process of euglycemic clamp 
 
 
Day 3: Hyperglycemic clamp without the test meal 
The HGC without the test meal was performed in the similar manner as HGC with test meal 
except that the meal was not ingested at 120 minutes. The goal of the HGC without the test 
meal on the third day of visit 1 was to assess the ß-cell response to the HGC without the meal 
test and to compare the results with that of the HGC with the test meal. 
3.3.3. First phase of caloric restriction 
As mentioned above, the caloric restriction started 2 weeks after visit 1 and lasted for 3 
months (Figure 4). During the 2 weeks before the caloric restriction, the subject had to fully 
comply with dietary and activity recommendations to keep a stable weight (± 2kg). The 
Go 
90 
mg/dl 
+/- insulin  
      bolus  
IV insulin and IV glucose infusion 
180 minute 
 -20 120 
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caloric restriction was divided into 2 phases. The first phase covered the first 10 days, during 
which the subjects had to stay in the hospital to ensure full compliance with protocol. The 
subjects performed the same calorie-restricted protocol as that of postoperative patients. The 
subjects were completely fasting during the first 3 days and were recommended to drink water 
or unsweetened tea of at least 2.5 liter/day. From day 4 to day 6, the calorie intake was 
increased slowly like in postoperative patients, using a commercially available product 
(BCM-basic; www.bcm.de). From day 6 to day 10, the intake was further increased (using the 
same commercially available formula diet) providing on average 700 kcal/day. The subjects 
were instructed to continue normal daily activity. Blood glucose, vital parameters, body 
weight, waist circumference, and VAS were measured every day. 
 
 
 
 
 
 
 
Screening         Visit 1                                                         Visit 2                               Visit 3 
 
Day   -21            -14                0                                             10                  30                     90 
 
             DP I            DP II                     DP III                           DP IV             DP V 
 
 
 
 
 
 
P-Protein; C-Lipid; C-Carbohydrate; DP-Dietary protocol; E-Energy; BCM-basic (formula 
diet). 
 
Figure 7: Dietary intervention of study 
 
 
Proportion:  
15% P 
30% L 
55% C 
Stable weight: ± 2kg 
 
Day 1-3: 0 kcal 
Day 4-6: increased slowly 
Day 6-10:Formula (BCM), 
700kcal/day 
P:L:C= 30:30:40 
 
1400 kcal/day 
Proportion: 
20% P 
30% L 
50% C  
 
P: 15E% ± 3: 12-18E% 
L: 30E% ± 6: 24-36% 
C: 55E% ± 11: 44-66E% 
 
700 kcal ± 140: 560-840 kcal 
P: 30E% ± 6: 24-36E% 
L: 30E% ± 6: 24-36% 
C: 40E% ± 8: 32-48E% 
 
1400 kcal ±280:1120-1680 kcal 
P:20E% ± 4: 16-24E% 
L:30E% ± 6: 24-36% 
C:50E% ± 10: 40-60E% 
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3.3.4. Visit 2 
Visit 2 occurred during the last 2 days of the first phase of caloric restriction (Figure 4). Visit 
2 included a short HGC without test meal at the first day and an EGC at the second day. The 
short HGC without test meal lasted for 120 minutes and was performed identical to the first 
120 minutes of HGC without test meal at the visit 1. The EGC at the second day was also 
performed in the same way as that at the visit 1. The goal of visit 2 was to assess the 
improvement of ß-cell response (first and second phase) to intravenous glucose infusion and 
the improvement of peripheral insulin sensitivity to exogenous insulin after the first phase of 
caloric restriction. Lipid profile, the clinical parameters such as body weight, WC, blood 
pressure, and pulse were also measured at the first day. 
3.3.5. Second phase of caloric restriction 
After the visit 2, the subject was discharged and started the second phase of caloric restriction. 
The second phase of the caloric restriction lasted until the end of study (Figure 4). Subjects 
were allowed to consume 1400 kcal/day and the proportions of protein, lipid, and 
carbohydrate were 20 %, 30 %, and 50 %, respectively. We regularly instructed them to 
continue the dietary intervention. Dietary compliance during the second phase was assessed 
by 2 dietary protocols (dietary protocol IV and dietary protocol V) (Figure 7). Dietary 
protocol IV estimated the food consumption for the first 30 days, and dietary protocol V 
estimated the food consumption for the last 50 days. Every dietary protocol included 3 
weekdays and 1 weekend-day. Based on these protocols, we calculated the amount of energy 
consumed and the proportion of the food components. The mean values of these two protocols 
were used to determine the compliance with dietary intervention (Figure 7). 
3.3.6. Visit 3 
Visit 3 occurred 3 months after starting caloric restriction. It included 2 days. The study 
procedures of these 2 days included the HGC with the meal on the first day and the EGC on 
the second day was performed identical to the first 2 days of visit 1. The lipid profile and 
other clinical parameters such as body weight, WC, blood pressure, and WC were measured 
on the first day. 
3.4. Sample preparation and laboratory analysis 
During the clamp, blood glucose was measured by the glucose oxidase method using 2 
standardized Bayer´s Contour® blood glucose analysers. The blood glucose was measured two 
times, and the mean value of these 2 separated values was used. 
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The blood samples for insulin and C-peptide were collected in Monovette EDTA blood 
collection tubes (Sarstedt). After collecting, the blood was centrifuged immediately, and 
serum samples were stored at -25oC. Insulin and C-peptide were measured by specific and 
sensitive sandwich immune-luminescence assay (ILMA). 
3.5. Calculation 
- Acute insulin response to intravenous-glucose induced hyperglycemia (AIRg) was 
estimated to be the mean increment of insulin during the first 10 minutes of HGC with 
the test meal [7]. 
- The basal insulin concentration was obtained as the mean of the four samples drawn at 
-20, -10, -5, and 0 minute.  
- The plasma insulin concentrations of the first 10 minutes and from 60 to 120 minutes 
were obtained as the mean of all samples in each time period. 
-
 First-phase insulin response:  (µU/ml) = MIC0-10 min – MICbasal 
- The incretin effect (%) was calculated as  
           MIC(125-360 min) – MIC(90-120 min) 
- Incretin effect (%) =                                                                 x 100       [33] 
          MIC(125-360 min) 
- Where MIC(90-120 min) and MIC(125-360 min) are the means of insulin concentration from 
90 to 120 min and from 125 to 360 min for HGC with test meal, respectively. 
- Glucose infusion rate (GIR) was calculated after at last 60 minutes of HEC and was 
expressed as mg/kg/min. 
- The insulin sensitivity index (ISI = GIR/insulin concentration) was expressed as 
mg.kg-1.min-1/µU.ml-1. 
- The insulin sensitivity to exogenous insulin was estimated by GIR and ISI. 
- The deposition index (DI=AIRg X ISI) was used to estimate the appropriateness of 
acute ß-cell response relative to prevailing insulin sensitivity [43]. 
- Insulin resistance index (HOMA-IR) was calculated as:  
- fasting plasma insulin (µU/mL) x fasting plasma glucose (mg/dl)  
405 
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3.6. Data analysis 
Statistical analysis is conducted using IBM SPSS statistics 20 and GraphPad Prism 5. Data 
are presented as the mean ± SEM. Paired t-tests are used to compare data between visit 1 and 
visit 2, visit 1 and visit 3.  Spearman´s correlation was used to estimate the correlation 
between degree of body weight loss and degree of improved glucose metabolism. Statistical 
significance was set at a p-value less than 0.05. 
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4. RESULTS 
Twelve obese and diabetic subjects (4 men and 8 women, mean age 50.2 ± 2.2 years) were 
evaluated in the study. All subjects completed all phases of the study and participated in all 
visits. Serious adverse events did not happen during the study.  
4.1. Compliance of subjects with caloric restricted intervention 
Caloric intake and macronutritient intake is shown in Table 2 and Figure 8. The average 
energy intake during the first and the second phase of caloric restriction was 678.8 ± 47.8 and 
1407.3 ± 52.7 kcal/day, respectively. Both values are within the range of the protocol (560-
840kcal/day during the first phase and 1120-1680 kcal/day during the second phase).  
Table 2: Energy intake and proportion of food components (N=12) 
Parameters Before study 1st phase of CR 2nd phase of CR 
Energy intake (kcal/day) 2630 ± 141.9 678.8 ± 47.8*** 1407.3 ± 52.7*** 
Protein (%) 19.4 ± 0.7 30.4 ± 1.5*** 21.9 ± 0.6** 
Lipid (%) 36.7 ± 1.6 31.9 ± 1.1 29.8 ± 1.3** 
Carbohydrate (%) 43.3 ± 1.4 37.9 ± 1.0* 48.1 ± 1.8* 
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Figure 8: Compliance of subjects with caloric restricted intervention described  
by energy intake (A) and proportion of food components (B) 
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During the first phase, three subjects did not fully comply with caloric restriction. Of these 
three subjects, one consumed 164 kcal/day more than the accepted upper limit and two 
consumed less than the accepted lower limit, (one 144 kcal/day and one 191 kcal/day less 
than the lower limit value). During the second phase, eleven subjects complied fully with 
caloric restriction with one subject consumed 91.5 kcal/day less than the accepted lower limit. 
4.2. Weight loss and clinical parameters 
Changes in body weight and clinical parameters are shown in Table 3 and Figure 9. Before 
the caloric restriction, mean BMI was 46.0 ± 2.1 kg/m2. Nine subjects had grade III obesity 
(BMI ≥ 40kg/m2), and three subjects had grade II obesity (35 kg/m2 ≤ BMI < 40 kg/m2). All 
subjects had central obesity (evaluated by waist circumference ≥ 94cm for men and ≥ 80cm 
for women).  
Table 3: Effect of caloric restriction on body weight and clinical parameters (N=12) 
Parameters Visit 1 Visit 2 Visit 3 
Weight (kg) 133.5 ± 6.6 127.0 ± 6.3(***) 120.5 ± 5.7*** 
BMI (kg/m2) 46.0 ± 2.1 43.8 ± 2.0(***) 41.7 ± 2.1*** 
Excess weight loss (%)  11.4 ± 1.0 22.3 ± 3.8 
Waist circumference (cm) 136.7 ± 5.3 131.5 ± 5.3 126.2 ± 4.6*** 
Sys-Blood pressure (mmHg) 132.9 ± 4.1 129.7 ± 3.5 126.9 ± 2.7 
Dia-Blood pressure (mmHg) 75.2 ± 2.4 69.2 ± 3.0 69.8 ± 2.9 
 
Weight loss was observed in all subjects after the first phase and the second phase of caloric 
restriction. Mean body weight decreased from the initial value of 133.5 ± 6.6 kg to 127.0  ± 
6.3 kg (P < .001) at visit 2 and to 120.5 ± 5.7 kg (P < .001) at visit 3. The mean percentage of 
excess weight loss was 11.4 ± 1.0 % at visit 2 and 22.3 ± 3.8 % at visit 3. The number of 
subjects who lost > 5 % of their initial body weight was seven and nine at visit 2 and visit 3, 
respectively. This decrease in weight was associated with a decrease in central obesity 
(estimated by waist circumference) from 136.7 ± 5.3 cm at visit 1 to 131.5 ± 5.3 cm (P < 
.001) at visit 2 and to 126.9 ± 2.7 cm (P < .001) at visit 3. There was an improvement in blood 
pressure at visit 2 and visit 3, although these changes were not significant. 
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Figure 9: Change of body weight after caloric restriction shown  
by weight loss (A) and excess weight loss % (B) 
 
 
4.3.Improvement in glucose metabolism 
Before the caloric restriction, the subjects had a mean duration of diabetes of 5.2 ± 0.7 years 
(from 1.4 to 10 years). Most of them (9 subjects) had good glycemic control with HbA1c ≤ 7 
%. Eight subjects took oral antidiabetic medications, two subjects received both oral 
medications and insulin, and two subjects performed life style modification. There was a 
significant improvement in main parameters of glucose metabolism after the caloric 
restriction. The decrease of fasting blood glucose was found in 11/12 subjects at visit 2 and in 
all subjects at visit 3. The mean of fasting blood glucose dropped by 18.4 ± 8.8 mg/dl (P < 
.01) at visit 2 and 23.1 ± 3.5 mg/dl (P < .001) at visit 3. The decrease of HbA1c was observed 
in 9/12 subjects, and the mean of HbA1c fell from the basal value of 6.7 ± 0.3 % to 6.2 ± 0.1 
% (P = .06) at visit 3 (Table 4 and Figure 10).  
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Table 4: Effect of caloric restriction on diabetic improvement (N=12) 
Parameters Visit 1 Visit 2 Visit 3 
Fasting glucose (mg/dl) 133.1 ± 6.4 114.6 ± 6.7(**) 110 ± 4.7*** 
HbA1c (%) 6.7 ± 0.3  6.2 ± 0.1 
Diabetic medication 
 Decrease 
 Withdrawing 
 Keeping same dose 
10  
 
10 
5/10 
0/10 
5/10 
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Figure 10: The improvement in fasting blood glucose (A) and HbA1c (B)  
after caloric restriction (N=12) 
The improvement in diabetes (simultaneous decrease of HbA1c and fasting blood glucose 
without the increase of diabetic medications) was observed in nine subjects. Among these 
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nine subjects, five decreased diabetic medications, four kept the same doses. Among the three 
remaining subjects, one improved in fasting glucose but without change of HbA1c and 
medication dose, while two had an improvement in fasting glucose and an increase in HbA1c. 
Of these latter two subjects, one had a duration of diabetes of 10 years, and one had very good 
glycemic control before the study (HbA1c = 5.6 % and fasting glucose = 104 mg/dl). Both 
had a rise of HbA1c (5.8 % at visit 1 compared to 6.0 % at visit 3, 5.6 % at visit 1 compared 
to 6.0 % at visit 3) and a decrease of fasting blood glucose (120 mg/dl at visit 1 compared to 
109 mg/dl at visit 3, 104 mg/dl at visit 1 compared to 97 mg/dl at visit 3). 
4.4. Mechanisms of improved glucose metabolism 
The mean values of glucose concentrations during the hyperglycemic and euglycemic clamps 
are shown in Figure 11. Clamped levels of blood glucose showed a very small fluctuation 
(during the clamp). The mean increments above fasting blood glucose of clamped blood 
glucose during hyperglycemic lamps were 99.5 ± 0.7 mg/dl at visit 1 and 99.3 ± 0.4 mg/dl at 
visit 3 (Figure 11A). The means of clamped blood glucose (120-180 min) during EGC at visit 
1, visit 2, and visit 3 were 89.8 ± 0.5, 89.2 ± 1.6, and 90.9 ± 0.9 mg/dl, respectively (Figure 
11B). 
4.4.1. Incretin effect 
Incretin effect was observed after the test meal during the HGC, and it was not present during 
the HGC without the test meal at day 3 of visit 1. The incretin effect, which was estimated by 
the increment of values (glucose infusion rate, insulin concentration, and C-peptide 
concentration) between 90 – 120 min and 125 – 360 min, was larger at visit 3 in comparison 
with that at visit 1 (Figure 12A, 12B, 12C). A two-fold increase of insulin concentration after 
the test meal compared to that before the test meal was found at visit 1. Meanwhile, a four-
fold increase was observed at visit 3. This difference was also present for the glucose infusion 
rate and C-peptide concentration (Figure 13, Table 5). Percent incretin effect for insulin 
increased from the initial value of 51.2 ± 5.0 % to 70.6 ± 4.7 % (P < .05) at visit 3. The 
improvement in the percent incretin effect was also observed when it was estimated by 
glucose infusion rate and C-peptide concentration (Figure 14). 
 
 
26 
 
(A)
-60 -30 0 30 60 90 120 150 180 210 240 270 300 330 360
0
100
200
300
400
Visit 1
Visit 2
Visit 3
Time (min)
B
lo
o
d 
G
lu
co
se
 
(m
g/
dl
)
 
 
 
(B)
-30 0 30 60 90 120 150 180
0
30
60
90
120
150 Visit 1
Visit 2
Visit 3
Time (min)
B
lo
o
d 
G
lu
co
se
 
(m
g/
dl
)
 
Figure 11: Blood glucose during hyperglycemic clamp (A) and euglycemic clamp (B) 
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Figure 12A: Changes in the incretin effect described by glucose infusion rate  
during the HGC with the test meal. For comparisondata from  
visit 1 day 3 (HGC without the test meal) are also shown (N=12). 
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Figure 12B: Changes in the incretin effect described by plasma insulin concentration 
during the HGC with the test meal. For comparisondata from  
visit 1 day 3 (HGC without the test meal) are also shown (N=10). 
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Figure 12C: Changes in the incretin effect described by plasma C-peptide concentration 
during the HGC with the test meal. For comparisondata fromvisit 1 day 3  
(HGC without the test meal) are also shown (N=10). 
 
 
Table 5: Effect of caloric restricted intervention on the incretin effect (N=10) 
 
 
 
Parameters Visit 1 Visit 3 
Increase after test meal (fold) 
GIR 
Insulin 
C-pepetide 
 
2.2 ± 0.3 
2.2 ± 0.2 
2.0 ± 0.2 
 
3.5 ± 0.5 
4.4 ± 0.9 
3.1 ± 0.5 
Incretin effect (%) 
GIR 
Insulin 
C-peptide 
 
44.4 ± 6.8 
51.2 ± 5,0 
47.5 ± 4.1 
 
67.0 ± 3.7** 
70.6 ± 4.7(*) 
63.1 ± 4.2(*) 
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Figure 13: The difference of glucose infusion rate (A, N=12), insulin concentration (B, 
N=10), and C-peptide concentration (C, N=10) before and after the test meal at visit 1 and 
visit 3. The glucose infusion rate between 90-120min and 125-360min increased 2.2-fold at 
visit 1, while it increased 3.5-fold at visit 3 (A). A similar effect was seen when insulin (B) 
and C-peptide (C) data were analyzed. 
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Figure 14: The increase in the incretin effect before and after caloric restriction estimated  
by glucose infusion rate (A, N=12), insulin concentration (B, N=10), 
and C-peptide concentration (C, N=10) 
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4.4.2. Insulin sensitivity 
Insulin sensitivity was estimated by several variables. As assessed by the EGC, insulin 
sensitivity improved significantly at visit 3. An increased  glucose infusion rate during the last 
60 min of EGC was present in 11/12 subjects at visit 3, and the mean of glucose infusion rate 
increased from 3.7 ± 0.5 at visit 1 to 5.5 ± 0.6 mg/kg/min  at visit 3 (P < .01). Similarly, an 
increase of the insulin sensitivity index (ISI) was observed in all subjects, and the mean of 
insulin sensitivity index increased from 22.9 ± 3.8 at visit 1 to 45.5 ± 9.8  at visit 3 (P < 0.05) 
(Table 6, Figure 15). As estimated by HOMA-IR, insulin sensitivity also improved 
significantly at visit 3 (6.7 ± 0.9 at visit 1 and 2.7 ± 0.8 at visit 3, P < .001), and HOMA-IR 
decreased in all subjects at visit 3. On the other hand, fasting concentration of insulin 
decreased significantly at visit 3 (compared to visit 1). Although caloric restriction during the 
first phase (between visit 1 and 2) resulted in a small improvement in GIR, ISI, HOMA-IR, 
and fasting insulin concentration, these changes were not significant.  
 
Table 6: The effect of caloric restriction on insulin sensitivity (N=12) 
Parameters Visit 1 Visit 2 Visit 3 
Fasting insulin (µU/ml) 20.0 ± 2.5 15.9 ± 2.7 9.3 ± 2.5* 
Fasting C-peptide (ng/ml) 12.4 ± 3.4 12.2 ± 3.0 7.4 ± 1.5 
GIR (mg/kg/min) 3.7 ± 0.5 3.9 ± 0.3 5.5 ± 0.6** 
ISI 22.9 ± 3.8 27.4 ± 5.0 45.5 ± 9.8(*) 
HOMA-IR 6.7 ± 0.9 4.6 ± 1.0 2.7 ± 0.8*** 
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Figure 15: The improvement in insulin sensitivity after caloric restriction shown  
by GIR (A,B, N=12) and ISI (C, N=10) during the last 60 minutes of EGC. 
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4.4.3. ß-cell function 
ß-cell function was determined by acute insulin response to hyperglycemia (AIRg) and 
deposition index (DI). AIRg was observed for both insulin and C-peptide concentrations 
during the first 10 min of the HGC (Figure 16A and 16B). Caloric restriction induced an 
increase of AIRg for insulin and C-peptide at visit 2 and visit 3. However, the increase 
reached statistical significance only for insulin at visit 2 (Table 7, Figure 16C and 16D). 
Deposition index (a useful measure of ß-cell compensation) increased from 244.2 ± 131.1 at 
visit 1 to 516.0 ± 237.5 (P > 0.05) at visit 2 and to 542.1 ± 201.0 (P < .05) at visit 3. The 
increase of deposition index (estimated as AIRg X ISI) resulted from the combined increase 
of acute insulin response and insulin sensitivity index. Acute insulin response increased from 
8.4 ± 3.5 µU/ml at visit 1 to 14.5 ± 5.1 µU/ml at visit 2 and to 12.3 ± 2.8 µU/ml at visit 3 
(Table 7). Meanwhile, insulin sensitivity index also increased from 22.9 ± 3.8 at visit 1 to 
27.4 ± 5.0 at visit 2 and to 45.5 ± 9.8 at visit 3 (Table 6). 
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Figure 16A: The changes of acute response of ß cells described  
by insulin concentration (N=10). 
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Figure 16B: The changes of acute response of ß cells described  
by C-peptide concentration (N=10). 
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Figure 16C: Insulin concentration during AIRg increases 
at visit 2 and visit 3 in comparison with that at visit 1 (N=10) 
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Figure 16D: C-peptide concentration during AIRg increases 
at visit 2 and visit 3 in comparison with that at visit 1 (N=10) 
 
 
Table 7: Effect of caloric restriction on ß cell function (N=10) 
Parameters Visit 1 Visit 2 Visit 3 
AIRg 
Insulin (µU/ml) 
C-peptide (ng/ml) 
 
8.4 ± 3.5 
0.4 ± 0.9 
 
14.5 ± 5.1(*) 
3.1 ± 1.7 
 
12.3 ± 2.8 
2.5 ± 1.1 
Disposition index 244.2 ± 131.1 516.0 ± 237.5 542.1 ± 201.0(*) 
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4.5. Clinical improvement in diabetes and result of mechanistic studies (on individual 
basis) 
Although the clinical improvement in diabetes was less pronounced in 2/12 subjects (subject 
one and subject two in Table 8), mechanistic studies (incretin effect, insulin sensitivity, and ß-
cell function) show an improvement in both subjects. Among the remaining ten subjects 
having clear clinical improvement, six had an improvement in most mechanisms, four had the 
improvement in the incretin effect and the insulin sensitivity (Table 7). 
 
Table 8: Clinical improvement and improved mechanisms at visit 3: GIR – Glucose infusion 
rate; ISI – Insulin sensitivity index; AIR-Insulin – Acute insulin response estimated for 
insulin; AIR-C-peptide – Acute insulin response estimated for C-peptide; DI – Disposition 
index (subjects 10-12 not all data available). (+): improvement; (-): no improvement; (+/-): 
decreased fasting blood glucose and increased HbA1c. 
  Improved mechanisms 
Incretin effect (%) Insulin sensitivity ß-cell function 
GIR Insulin C-peptide GIR ISI HOMA 
AIR-
Insulin 
AIR-C-
peptide DI 
1 -/+ + + + + + + + + + 
2 -/+ + + + + + + - + - 
3 + + + + + + + + + + 
4 + + + + - + + - - - 
5 + - - + + + + + + + 
6 + + + + + + + + + + 
7 + + + + + + + - + + 
8 + - + - + + + + + + 
9 + + - + + + + + + + 
10 + +   +      
11 + +   +      
12 + +   +      
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4.6. Lipid profile  
Changes of lipid parameters are shown in Table 9 and Figure 17. Caloric restriction induced 
significant decreases in total-cholesterol and Lp(a) at visit 2 and visit 3. Although 
triglycerides and VLDL-cholesterol tended to decrease at visit 2 and visit 3, the changes in 
these parameters were not significant. LDL-cholesterol decreased significantly only at visit 3, 
while, VLDL-triglycerides decreased significantly only at visit 2. Interestingly, HDL-
cholesterol decreased significantly at visit 2. 
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Figure 17: The effect of caloric restriction on lipid parameters; Chol – total cholesterol; TG – 
triglycerides; HDL – HDL-cholesterol; LDL – LDL-cholesterol; VLDL-C – VLDL-
cholesterol; VLDL-T – VLDL-triglyceride; Lp(a) – Lipoprotein (a) 
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Table 9: Effect of caloric restricted intervention on lipid metabolism (N=12) 
Lipid parameters Visit 1 Visit 2 Visit 3 
Cholesterol (mg/dl) 182.8 ± 11.9 166.4 ± 12.1(**) 163.8 ± 11.3** 
Triglycerides (mg/dl) 127.1 ± 21.5 95.3 ± 9.5 105.2 ± 12.6 
HDL-chol (mg/dl) 47.0 ± 3.0 38.8 ± 2.5(***) 42.6 ± 2.2 
LDL-chol (mg/dl) 114.2 ± 9.2 113.2 ± 11.4 103.4 ± 9.0** 
VLDL-cholesterol (mg/dl) 21.7 ± 4.8 14.3 ± 2.0 17.6 ± 2.6 
VLDL-triglyceride (mg/dl) 105.5 ± 21.7 70.3 ± 11.6(*) 90.3 ± 13.4 
Lp(a) (mg/dl) 27.7 ± 7.6 37.4 ± 6.7(*) 37.2 ± 7.5* 
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5. DISCUSSION 
5.1. Caloric intake and weight loss 
The protocol of our study was such that we tried to imitate nutritional intake following 
bariatric surgery. During the first phase of the study (day 0 until day 10 of caloric restriction) 
average caloric intake was 678.8 ± 47.8 kcal/day and while it was 1400.8 ± 52.0 kcal/day 
during the second phase of caloric restriction (day 11 until 3 months). The recommended 
caloric intake following bariatric surgery is about 500 kcal/day for the first 2 weeks after 
surgery [44].  Golpaie A et al. evaluated caloric intake in 30 severely obese subjects treated 
with laparoscopic restrictive bariatric surgery and reported a mean caloric intake of 621.7 ± 
301.0 kcal/day during the first 6 weeks following surgery [45]. Similarly, Trostler N et al. 
reported a caloric intake of 694 ± 105 kcal/day in men and 579 ± 111 kcal/day in women 
during the first 30 days after gastric bypass Roux-en-Y for morbidly obese patients [46]. 
Thus, the caloric intake immediately after bariatric surgery is very homogenous in previously 
published studies and is very similar to the one observed during the the first phase of caloric 
restriction in our study. This also indicates that our subjects were very compliant with the 
protocol during this study period. The fact that subjects were admitted to the hospital was an 
important factor in achieving this compliance. While caloric intake shows little variation 
immediately after surgery, it is more variable 3 months later. The caloric intake 3 months after 
bariatric surgery was 535 ± 158 kcal/day and 529.4 ± 300.2 kcal/day in studies of Trotsler N 
et al. and Dias MC et al., respectively [46, 47]. Bobbioni-Harsch E et al. showed a caloric 
intake of 966 ± 42 kcal/day at 3 months after gastric bypass in a cohort of fifty obese women 
[48]. Another study reported a caloric intake of 899 ± 41 kcal/day and 871 ± 47 kcal/day at 4 
months after gastric bypass and sleeve gastrectomy, respectively [49]. Although caloric intake 
during the second phase of caloric restriction in our study is higher than in the above 
mentioned studies, it is still significantly lower compared to the period before the study.  
The weight loss observed in our study is due to caloric restriction. There is abundant evidence 
that bariatric surgery induces weight loss short term after surgery. A decrease in BMI at visit 
2 in our study is line with that in postoperative patients in some previously published studies. 
Rizeello M et al. described a decrease from the initial value of 44.76 ± 7.2 kg/m2 to 43.3 ± 7.7 
kg/m2 at 15 days after sleeve gastrectomy [23]. Umeda LM et al. studied 10 obese patients 
with type 2 diabetes treated with gastric bypass and showed a decrease from 39.7 ± 1.9 kg/m2 
before surgery to 37.0 ± 2.1 kg/m2 at 7 days after surgery [25]. The effect on BMI 3 months 
after surgery is much more variable ranging from 4 to 10 kg/m2 [25, 46-48, 50-53]. The BMI 
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in our study dropped by 5.7 kg/m2 at visit 3 (3 months). This decrease is less than the one 
described in some but not all previously published studies. While Trostsler N et al. and 
Harsch E et al. [46, 48] describe a decrease of more than 8 kg/m², Ballantyne GH et al. and 
Dias MC et al. [47, 50] describe a decrease similar to the one observed in our study. These 
differences may be the consequence of different caloric intakes in the different studies. 
5.2. Improvement in glucose metabolism  
Bariatric surgery leads not only to weight loss but also to an improvement in glucose 
metabolism [50, 52, 54]. The role of caloric restriction and weight loss in improved glucose 
metabolism after bariatric surgery is still controversial. Although the role of caloric restriction 
in the improvement in glucose metabolism is established in the literature, many studies show 
that the improvement in glucose metabolism occurs after bariatric surgery before any 
significant weight loss is observed. The data from these studies support a weight-loss 
independent mechanism of improved glucose metabolism after bariatric surgery [23-25, 27, 
28, 55]. Our study shows that the improvement in glucose metabolism was present in most of 
the subjects despite the fact that the weight loss was less or equivalent to that observed after 
bariatric surgery. The improvement in glucose metabolism at visit 2 in our study was assessed 
by the significant decrease of fasting blood glucose. Because visit 2 occurred on the 10th day 
of first phase of caloric restriction, changes in HbA1c and diabetic medications were not 
expected. The diabetic improvement at visit 3 was evident by a decrease in fasting glucose, 
medication doses, and HbA1c. Two subjects had an increase in HbA1c (despite a decrease in 
fasting blood glucose) at visit 3. One subject had aduration of diabetes of 10 years. It has been 
described extensively in the past that duration of diabetes and glycemic response to treatment 
is correlated to each other. Increasing duration of diabetes is associated with decreasing ß-cell 
function [56, 57] and insulin resistance may increase with duration of diabetes [58]. Duration 
of diabetes is also a major predictor of whether or not diabetes remission will occur after 
bariatric surgery in patients with type 2 diabetes, and it seems that ten-year duration is a cut 
point in this respect [54, 59, 60].  The other subject with an increase in HbA1c had a baseline 
value of 5.6 % at visit 1 which increased to 6.0 % at visit 3. However, fasting blood glucose 
dropped by 7 mg/dl, and the dose of metformin decreased from 1.5 g/day at visit 1 to 1 g/day 
at visit 3. In our study, the improvement in glucose metabolism occurred in the context of a 
significant weight loss. However, the degree of improvement of fasting glucose and of HbA1c 
was not associated with the degree of weight loss. This dissociation could be explained by a 
small variation in weight loss and by the small study group. Some studies report a weight loss 
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independent effect of caloric restriction on the improvement in glucose metabolism [12]. Our 
study design does not allow to seperate effect of caloric restriction from the effect of weight 
loss in the improvement in glucose metabolism. After bariatric surgery, weight loss 
commonly occurs in the context of caloric restriction. The results in our study confirm the 
role of caloric restriction and weight loss in the improvement in glucose metabolism, although 
there may be additional factors mediating the improved glucose metabolism after bariatric 
surgery. 
5.3. Mechanisms of the improved glucose metabolism 
5.3.1. Incretin effect 
An improved incretin effect (increase in incretin levels and effect) is considered to be an 
important mediator for the improved glucose metabolim following bariatric surgery [41, 61]. 
Because caloric restriction and weight loss occur very early after bariatric surgery, it is still 
controversial whether the improved incretin effect results from caloric restriction and weight 
loss or from other additional factors [62, 63].  
Our study assessed the effect of caloric restriction and weight loss on the incretin effect. The 
results from our study highlight two important aspects of the incretin effect.  
The first is that the incretin effect is retained in morbidly obese patients with type 2 diabetes. 
This is evident by comparing the results of the HGC with test meal at day 1 of visit 1 with 
those of the HGC without test meal at day 3 of visit 1. The significant increase of plasma 
insulin concentration, C-peptide concentration, and glucose infusion rate after the test meal 
indicates an increase in glucose-stimulated insulin secretion after the test meal. Although 
GLP-1 and GIP were not quantified in our study, the increase in glucose-stimulated insulin 
secretion after the test meal most likely corresponds to the effect of incretin hormones on beta 
cells. Thus the incretin effect is retained in the subjects in our study. Many studies show that 
the incretin effect in individuals with T2DM is impaired compared to controls [64]. However, 
there is evidence that in individuals with well-controlled diabetes, the effects of endogenous 
GLP-1 on insulin secretion is comparable to that in nondiabetic individuals [65]. Most of the 
patients included in the current study had well-controlled diabetes with an HbA1c < 7 %. 
Obesity also induces a decreased GLP-1 secretion which is related to the impaired incretin 
effect [66] 
The second observation is the significant improvement in the incretin effect after caloric 
restriction and weight loss. The data from our study support a significant improvement in 
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glucose-stimulated insulin secretion after the test meal at visit 3. This improvement may result 
from an improved secretion of endogenous incretin hormones or/and an improvement in the 
sensitivity of insulin secretion to endogenous incretin hormones. Because incretin hormones 
were not quantified, these two features cannot be separated in our study. The effects of 
incretin hormones on glucose metabolism have been shown by the administration of GLP-1 
receptor agonists and DPP-4 inhibitors both also used for treatment of diabetes. Studies 
evaluating the effect of dietary interventions on the incretin effect in individuals with type 2 
diabetes are scarce. Laferrere B et al. showed an unchanged GLP-1 and GIP secretion after an 
hypocaloric diet, while there was an increased GLP-1 and GIP secretion after gastric bypass 
surgery in patients with type 2 diabetes despite similar weight loss [28]. Similar results were 
also described by Valderas JP et al. in obese patients without diabetes treated with sleeve 
gastrectomy or with medication for obesity. Although patients achieved similar weight loss 2 
months after the treatment for obesity, an increase in GLP-1 secretion was present only after 
sleeve gastrectomy, not after medical treatment [40]. The differences between our study and 
the above two studies may be due to the absence of diabetes (in study of Valderas JP et al.), a 
smaller weight loss (9.8 kg in study of Laferrere B et al), and shorter duration dietary 
intervention (two months in study of Valderas and one month in study of Laferrere).  
Thus, our study confirms that caloric restriction and weight loss leads to a significant 
improvement in the incretin effect that may be one of the major mediators of the improved 
glucose metabolism. 
5.3.2. Insulin sensitivity 
Bariatric surgery induces an improvement in insulin sensitivity that contributes to the 
improved glucose metabolism after surgery. Interestingly, many previous studies show that 
the improvement in insulin sensitivity occurs very early after both malabsorptive and 
restrictive procedures before any significant weight loss occurs. In the studies of Rizzello M 
et al., Peterli R et al., and Wickremesekera K et al., insulin sensitivity (estimated by HOMA-
IR and EGC) improved already one week after sleeve gastrectomy and gastric bypass before 
weight had significantly dropped. The authors of these studies concluded that a hormonal 
mechanism may be involved in these changes [23, 63, 67]. Hady HR et al. studied the 
improvement in insulin sensitivity on day 7 after restrictive bariatric surgery and showed that 
the insulin sensitivity improved significantly before significant weight loss occurred. Our 
study shows a significant improvement in insulin sensitivity in the context of a significant 
weight loss following caloric restriction. The improvement in insulin sensitivity was 
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estimated by changes in fasting insulin concentration, HOMA-IR, glucose infusion rate, and 
insulin sensitivity index during the EGC performed before and after caloric restriction. These 
variables tended to change (decrease in fasting insulin concentration and HOMA-IR, increase 
in glucose infusion rate and insulin sensitivity index during the EGC) at visit 2 and improved 
significantly at visit 3. The correlation between weight loss and insulin sensitivity has been 
established in the literature [68-70]. Many possible mechanisms for the improvement in 
insulin sensitivity after weight loss have been discussed in previous studies. Schenk S et al. 
showed that weight loss leads to decreased systemic fatty acid mobilization and uptake 
resulting in improvement in insulin sensitivity [71]. The improvement in hepatic insulin 
sensitivity after weight loss is related to a decrease in liver fat [72, 73]. Weight loss may also 
decrease subclinical inflammation which plays an important role in inducing and maintaining 
insulin resistance [74]. 
The degree of the improvement in insulin sensitivity seems to be related to the degree of 
weight loss. Borges RL et al. studied female patients with abdominal obesity and showed that 
a weight loss of more than 5 % was associated with improved insulin sensitivity [75]. The 
result in the study by Borges would fit to the observations from our study, where no 
significant improvement in insulin sensitivity was observed at visit 2 with a weight loss of 4.9 
± 0.3 %, while there was a significant improvement at visit 3 with a weight loss of 9.5 ± 1.3 
%. Interestingly, although the decrease in body weight between visit 1 and visit 2 (6.5 kg, 
after 10 days of caloric restriction) was similar to that between visit 2 and visit 3 (also 6.5 kg, 
after 10 weeks), the difference in insulin sensitivity was significant only between visit 1 and 
visit 2, but not between visit 2 and visit 3. This implicates that acute or chronic weight loss 
may be related to the improvement in the insulin sensitivity. Very few studies have addressed 
this issue previously. Kirk E et al. studied the effect of acute caloric restriction on the insulin 
sensitivity and described that glucose infusion rate during EGC changed at 11 weeks with 
weight loss of 7.5 ± 0.4 %, but not at 48h with weight loss of 2.0 ± 0.2 % [73]. However, this 
difference may result from the differences in lost weight rather than differences in time. The 
role of weight loss on the improvement in the insulin sensitivity early after bariatric surgery 
has not been evaluated, while a number of studies have evaluated the longer term effect of 
weight loss following bariatric surgery on this parameter. In the studies of Valdera JP et al. 
and Nosso G et al, the improved insulin sensitivity was observed when significant weight loss 
had occurred 2 months and 3 months after sleeve gastrectomy, respectively. These authors 
also mention the role of weight loss in the improved insulin sensitivity [40, 52]. In the study 
by Hady et al. HOMA-IR had improved on the 7th day after surgery before any significant 
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weight loss had occurred, but both improvement in insulin sensitivity and weight loss 
continued at 1 and 3 months after surgery [21].  
The results from our study confirm that caloric restriction and weight loss lead to an 
improvement in insulin sensitivity. The degree of improvement may be related to the degree 
of weight loss but also to the duration of weight loss. 
5.3.3. ß-cell function 
An absence or decrease in the acute phase (first phase) of insulin secretion is commonly 
observed in patients with type 2 diabetes mellitus. In our study, the AIRg was 8.4 ± 3.5 µU/ml 
for insulin and 0.4 ± 0.9 ng/ml for C-peptide at visit 1. AIRg in our study was blunter than 
that in some previous studies which investigated the AIRg by HGC in normal individuals. 
Caumo A et al. used HGC to investigate the AIRg in 7 normal subjects and reported that 
AIRg was approximately 200 pmol/l (28.8 µU/ml) for insulin and 0.5 mmol/l (1.5 ng/ml) for 
C-peptide [76]. Many studies show that bariatric surgery leads to an improvement in the acute 
phase insulin secretion which may mediate the improvement in glucose metabolism after 
surgery. However, the role of caloric restriction and weight loss for the improvement in AIRg 
after bariatric surgery is still unclear. AIRg restoration was present one month after BPD in 
type 2 diabetic patients and was associated with normalized fasting blood glucose in the study 
of Briatore L e al. [77]. Salinari S et al investigated the acute insulin secretion one month after 
malabsorptive surgery in nine morbidly obese patients with type 2 diabetes and reported that 
the full normalization of the acute insulin secretion may be related to changes in intestinal 
factors [78]. The results from our study show an improvement in the acute insulin secretion at 
visit 2 and visit 3, although a significant improvement was observed only at visit 2. We 
understand that there are some limitations of using peripheral insulin and C-peptide 
concentrations to estimate the acute insulin secretion, which include the primary hepatic 
degradation of insulin and the peripheral clearance of insulin and C-peptide. When only 
peripheral insulin and C-peptide are used, the first phase insulin secretion may be delayed and 
blunted [76]. However, the above limitations may be negligible since the acute insulin 
secretion was estimated before and after caloric restriction (the same limitations are present at 
both time points). Because the improvement in insulin sensitivity was not significant and the 
incretin effect was not measured  at visit 2, the improvement in the acute insulin secretion was 
the only mechanism contributing to the improved glucose metabolism at that time point. 
Insulin is an essential hormone in glucose metabolism. It stimulates glucose uptake and 
inhibits endogenous glucose production. Thus, the improvement in first phase insulin 
secretion may lead to an improvement in all insulin-related processes, particularly in 
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postprandial glucose homeostasis [79]. Mitrakou A al. studied the relation between 30 min 
insulin levels and 2-hour blood glucose levels after an oral glucose test and showed that the 
improved acute insulin secretion seems to ensure a better postprandial blood glucose [80]. 
The correlation between the impairment of the acute insulin secretion and the impaired fasting 
glucose was also described in previous studies. Kanat M et al. studied ß-cell function in 
patients with impaired fasting glucose and describes an impaired first phase secretion of 
insulin [81]. Ozaki K et al. studied 8923 subjects and shows that there is a decrease in the 
acute insulin secretion in patients with fasting plasma glucose > 110 mg/dl [82].  
In type 2 diabetes mellitus, it is likely that insulin resistance precedes the impaired ß-cell 
function. Insulin resistance modifies ß-cell function in order to maintain a normal glucose 
homeostasis [83]. The relationship between the insulin sensitivity and ß-cell function is that as 
insulin sensitivity decreases, insulin secretion This relationship can be described and 
estimated by calculating the product of the acute insulin secretion  and insulin sensitivity 
index (deposition index: ID=AIRg X ISI). This product should be constant as long as the ß-
cell has enough capacity to compensate for an increase in insulin resistance. A decrease in this 
product indicates that ß cells are unable to fully compensate for insulin resistance. A decrease 
in this deposition index is commonly present in patients with impaired glucose tolerance, 
impaired fasting blood glucose, and type 2 diabetes [84]. The marked improvement (a two-
fold increase at visit 2 and visit 3) in the deposition index, which results from the combined 
improvement in AIRg and ISI, confirms the effect of caloric restriction and weight loss on ß-
cell function. 
5.4. Improvement in lipid metabolism 
Dyslipidemia is associated with an increased risk for cardiovascular disease. Although 
dyslipidemia was not pronounced before caloric restriction in our subjects, others report a 
common dyslipidemia in patients with T2DM and/or obesity [85, 86]. Despite the fact that 
dyslipidemia was only mild in our subjects triglycerides and non-HDL cholesterol decreased 
after caloric restriction in our study. The role of caloric restriction and weight loss on lipid 
metabolism has been described in previous studies. Bouwman FG et al. studied the effect of a 
very low caloric diet on lipid metabolism in overweight/obese subjects and reported a 
significant decrease in total cholesterol and LDL-cholesterol [87]. A significant decrease in 
triglycerides and total cholesterol was also observed after a weight loss of 11kg in a study of 
Jourdan M et al. [88]. Similarly, a decrease in triglycerides and non-HDL cholesterol was also 
observed after bariatric surgery. Hady et al. described a significant decrease in total 
cholesterol, triglycerides, and LDL-cholesterol in 100 obese patients 3 months after sleeve 
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gastrectomy [89]. In general, weight loss results in a decrease in triglycerides, VLDL-
triglyceride, and non-HDL cholesterol [90]. The decrease in triglycerides after weight loss 
may result from a decrease in the hepatic VLDL secretion, which may be the consequence of 
a decreased substrate flux (fatty acids) for VLDL production [91]. Non-HDL-cholesterol is a 
calculated parameter which encompasses LDL-cholesterol and remnant-cholesterol [92]. An 
improvement in this parameter reflects either an increase in HDL-cholesterol or a decrease in 
LDL and/or remnant cholesterol. In our study the improvement was mostly related to a 
decrease in remnant cholesterol. With respect to lipid metabolism, two unexpected changes 
were observed in our study: a decrease in HDL-cholesterol and an increase in Lp(a) were 
observed after caloric restriction and weight loss. Although most of the previous studies 
reported an increase in HDL-cholesterol after weight loss, a decrease was also observed in 
study of Thompson PD et al. [93]. The mechanism behind this observation is unclear but 
factors such as a dramatically decreased cholesterol intake during caloric restriction may be 
involved. Although elevated concentrations of Lp(a) are an established risk factor for 
cardiovascular diseases, very little is known about the metabolism of these particles. In 
contrast to other lipid parameters, Lp(a) levels change very little with lipid lowering agents. 
The effect of weight loss after bariatric surgery or other medical interventions on Lp(a) levels 
was variable in previous studies. Some studies show a significant decrease [94, 95], while 
others describe a significant increase or no change [96, 97]. The importance of this finding is 
currently unclear. 
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6. LIMITATIONS OF STUDY 
The current study has several limitations, some of which will be overcome by future analyses. 
We did not measure the incretin effect at visit 2 and therefore cannot say whether the incretin 
effect has improved already at visit 2 (like beta-cell function) or only at visit 3 (like insulin 
sensitivity). Furthermore, we so far have not measured incretin levels, which would be 
important to decide which of the involved hormones is primarily affected. Finally, we have 
not yet compared the results of the dietary intervention directly to the results of the surgical 
procedure. Measuring of incretin levels and direct comparison will be performed once the 
whole project is finished. 
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7. CONCLUSION 
In this study we used euglycemic and hyperglycemic clamps to evaluate the mechanisms of 
improved glucose metabolism in obese type 2 diabetic patients after caloric restriction and 
weight loss. The results of the current study show that: 
- Caloric restriction and weight loss lead to an improvement in glucose and lipid 
metabolism. 
- Improved glucose metabolism after caloric restriction and weight loss may be 
mediated by an improvement in the incretin effects, insulin sensitivity, and ß-cell 
function. 
- Improvement in glucose metabolism after bariatric surgery may be at least partly 
explained by caloric restriction and weight loss, not specific for the type of 
intervention. 
- Properly controlled studies with larger cohorts are necessary to elucidate the beneficial 
effects of bariatric surgery. 
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8. SUMMARY 
Objective 
The prevalence of obesity and type 2 diabetes mellitus is increasing quickly and is a major 
challenge to health care systems in the world. Bariatric surgery, which has been used widely 
for the treatment of morbidly obese patients, results not only in weight loss but also in a 
dramatic improvement in glucose metabolism. It is however unclear whether caloric 
restriction, weight loss or other surgery related factors mediate the improved glucose 
metabolism after bariatric surgery. Caloric restriction and weight loss occurs after bariatric 
surgery. However, there is evidence that the improvement in glucose metabolism is present 
immediately after surgery before any significant weight loss occurs. This evidence, therefore, 
supports the role of other weight loss-independent mechanisms in mediating the antidiabetic 
effect of bariatric surgery.  
To better understand the beneficial effects of bariatric surgery we designed a study in which 
morbidly obese subjects with type 2 diabetes follow a dietary protocol identical to one that 
patients receiving bariatric surgery have to follow. Our aim was to evaluate the role of caloric 
restriction and weight loss on glucose and lipid metabolism and analyse the mechanisms 
behind the improved glucose metabolism. 
Subjects and methods 
Morbidly obese subjects with type 2 diabetes followed the same dietary protocol as patients 
receiving bariatric surgery. The dietary protocol includes two phases. The first phase lasts 10 
days and subjects have to stay in hospital to comply fully with the protocol. The second phase 
lasts about 10 weeks and subjects are seen on an out-patient basis. Glucose and lipid 
metabolism was assessed before beginning caloric restriction (visit 1), and again after 2 weeks 
(visit 2, immediately after the first phase of caloric restriction) and 12 weeks (visit 3, 
immediately after the second phase of caloric restriction). The improvement in glucose 
metabolism was evaluated by changes in fasting blood glucose, HbA1c, and dose of 
antidiabetic medications. The improvement in lipid metabolism was evaluated by changes in 
lipid parameters. Potential mechanisms mediating the improved glucose metabolism, which 
were evaluated in the current study, include changes of the incretin effect, of insulin 
sensitivity and of ß-cell function. Incretin effect was estimated by the increment of values 
(glucose infusion rate, insulin concentration, and C-peptide concentration) between 90 – 120 
min (before test meal) and 125 – 360 min (after test meal) during the 6-hour hyperglycemic 
clamp with a test meal. Changes in insulin sensitivity were evaluated by changes in fasting 
plasma insulin, fasting plasma C-peptide, HOMA-IR, glucose infusion rate during last 60 
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minutes of a 3-hour euglycemic clamp, and the insulin sensitivity index. The changes in acute 
insulin secretion to hyperglycemia (AIRg) and disposition index were used to evaluate 
changes in ß-cell function. 
Results 
Twelve subjects were included in the study (8 women, 4 men; mean age 50.2 ± 2.2 years; 
mean duration of diabetes 5.2 ± 0.7 years). Most of the subjects had good glycemic control 
with mean HbA1c of 6.7 ± 0.3 % before beginning of caloric restriction. The average energy 
intake during the first phase and the second phase of caloric restriction was 678.8 ± 47.8 
kcal/day and 1407.3 ± 52.7 kcal/day, respectively. BMI decreased significantly from 46.0 ± 
2.1 kg/m2 to 43.8 ± 2.0 kg/m2 and 41.7 ± 2.1 kg/m2 at visit 2 and visit 3, p < .001 for both. 
There was a significant improvement in glucose metabolism after the first phase and the 
second phase of caloric restriction. This improved glucose metabolism is evident from a 
significant decrease in fasting blood glucose at visit 2 (decreased from 133.1 ± 6.4 mg/dl to 
114.6 ± 6.7 mg/dl, p < .01), and from the combined decrease in fasting blood glucose, HbA1c, 
and dose of antidiabetic medications at visit 3 (fasting blood glucose deceased from 133.1 ± 
6.4 mg/dl to 110 ± 4.7 mg/dl, p < .001; HbA1c decreased from 6.7 ± 0.3 % to 6.2 ± 0.1 %, p = 
0.06; dose of antidiabetic medications decreased in 5/10 subjects). A significant improvement 
in lipid metabolism was also present at visit 2 and visit 3 (total cholesterol decreased 
significantly from 182.8 ± 11.9 mg/dl to 166.4 ± 12.1 mg/dl and 163.8 ± 11.3 mg/dl; 
triglyceride decreased from 127.1 ± 21.5 mg/dl to 95.3 ± 9.5 mg/dl and 105.2 ± 12.6 mg/dl; 
LDL-cholesterol decreased significantly from 114.2 ± 9.2mg/dl to 113.2 ± 11.4 mg/dl and 
103.4 ± 9.0 mg/dl; VLDL-cholesterol decreased from 21.7 ± 4.8 mg/dl to 14.3 ± 2.0 mg/dl 
and 17.6 ± 2.6 mg/dl; VLDL-triglyceride decreased from 105.5 ± 21.7 mg/dl to 70.3 ± 11.6 
mg/dl and 90.3 ± 13.4 mg/dl). 
The improvement in glucose metabolism after caloric restriction in our study is accompanied 
by an improved incretin effect, enhanced insulin sensitivity, and better ß-cell function. Percent 
incretin effect increased significantly from visit 1 to visit 3 (not evaluated at visit 2) (from 
51.2 ± 5.0 % to 70.6 ± 4.7 %, P < .05, estimated by insulin; from 47.5 ± 4.1 % to 63.1 ± 4.2 
%, P < .05, estimated by C-peptide; from 44.4 ± 6.8 % to 67.0 ± 3.7 %, P <.01, estimated by 
glucose infusion rate). Enhanced insulin sensitivity was present only at visit 3, but not at visit 
2, and evident from the significant improvement in fasting plasma insulin (decreased from 
20.0 ± 2.5 µU/ml to 9.3 ± 2.5 µU/ml, p < .05), HOMA-IR (decreased from 6.7 ± 0.9 to 2.7 ± 
0.8, p < .001), glucose infusion rate during last 60 min of 3-hour euglycemic clamp (increased 
from 3.7 ± 0.5 mg/kg/min to 5.5 ± 0.6 mg/kg/min, p < 0.01), and insulin sensitivity index 
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(increased from 22.9 ± 3.8 to 45.5 ± 9.8, p < .05). Better ß-cell function was evident from a 
significant improvement in acute insulin secretion to hyperglycemia of ß cells at visit 2 (mean 
increment of insulin concentration between the fasting and the first ten minutes after glucose 
bolus during hyperglycemic clamp increased from 8.4 ± 3.5 µU/ml at visit 1 to 14.5 ± 5.1 
µU/ml at visit 2, p < .05) and a significant increase in disposition index at visit 3 (increased 
from 244.2 ± 131.1 at visit 1 to 542.1 ± 201.0 at visit 3, p < .05). The improvement in acute 
insulin secretion of ß cells was also present at visit 3 and the increase in disposition index was 
also present at visit 2. However, these changes were not significant. 
Conclusion 
This is a study evaluating the role of caloric restriction and weight loss on glucose and lipid 
metabolism and determining potential mechanisms mediating the improved glucose 
metabolism in obese type 2 diabetic patients. The results from our study show that caloric 
restriction and weight loss lead to a significant improvement in glucose and lipid metabolism. 
This improved glucose metabolism is mediated by an improved incretin effect, enhanced 
insulin sensitivity, and better ß-cell function. However, these improvements occur at different 
time points. While better beta-cell function is detectable very early after initiation of caloric 
restriction, insulin sensitivity only improves after several weeks and months. Due to a dietary 
protocol which is comparable to that of patients undergoing bariatric surgery, our subjects had 
the same average energy intake and weight loss after the first phase and second phase of 
caloric restriction. Thus, our study supports the concept that the improvement in glucose 
metabolism after bariatric surgery is at least partially (if not fully) explained by the caloric 
restriction and weight loss. Further studies directly comparing patients undergoing bariatric 
surgery with those undergoing a dietary intervention are necessary to further understand the 
beneficial effects of caloric restriction and weight reduction. 
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ZUSAMENFASSUNG 
Zielsetzung 
Die Prävalenz von Adipositas und Typ-2 Diabetes mellitus nimmt rasant zu und stellt eine 
große Herausforderung für Gesundheitssysteme weltweit dar. Bariatrische Chirurgie, die in 
großem Umfang zur Behandlung von krankhaft adipösen Patienten verwendet wird, führt 
nicht nur zu Gewichtsverlust, sondern auch zu einer dramatischen Verbesserung des 
Glukosemetabolismus. Trotzdem ist unklar, ob die kalorische Restriktion, der 
Gewichtsverlust oder andere, mit der Operation einhergehende Faktoren einen verbesserten 
Glukosestoffwechsel nach bariatrischer Chirurgie bedingen. Sowohl kalorische Restriktion als 
auch Gewichtsverlust treten nach einer bariatrischen Operation auf. Es gibt jedoch Belege 
dafür, dass eine Verbesserung des Glukosemetabolismus unmittelbar nach der chirurgischen 
Intervention und noch vor einem signifikanten Gewichtsverlust eintritt. Diese Erkenntnis 
unterstützt ihrerseits die Bedeutung von anderen, vom Gewichtsverlust unabhängig 
vermittelten Mechanismen, die für den antidiabetischen Effekt nach bariatrischen Operationen 
verantwortlich sein könnten.  
Um die positiven Auswirkungen der bariatrischen Chirurgie auf den Stoffwechsel besser 
verstehen zu können,  führten wir eine Studie durch, in der stark adipöse Typ-2-Diabetiker ein 
Ernährungsverhalten annehmen, das dem von bariatrisch operierten Patienten entspricht. Dies 
erlaubte uns die Rolle von kalorischer Restriktion und Gewichtsverlust bezüglich der 
Verbesserung des Glukose- und Lipidmetabolismus und die dahinter steckenden 
Mechanismen zu beurteilen. 
Probandenkollektiv und Methodik 
Stark adipöse Typ-2 Diabetiker ernährten sich analog zu Patienten, die sich einer bariatrischen 
Operation unterzogen. Der Ernährungsplan umfasste zwei Phasen. Die erste, zehntägige Phase 
mussten die Probanden in der Klinik verbringen um eine gute Compliance bezüglich der 
Ernährungsvorgaben zu erreichen. Die zweite Phase dauerte zehn Wochen und  fand bei den 
Probanden zu Hause statt. Daten zu Glukose- und Fettstoffwechsel wurden vor dem Beginn 
der kalorischen Restriktion (Visit 1), nach zwei Wochen (Visit 2, unmittelbar nach der ersten 
Phase der kalorischen Restriktion) und zwölf Wochen (Visit 3, unmittelbar nach der zweiten 
Phase der kalorischen Restriktion) erhoben. Die Verbesserung des Glukosemetabolismus 
wurde in Form von einer veränderten Nüchternblutglukose, des HbA1c-Werts  und der Dosis 
der antidiabetischen Medikamente erfasst.  Die Verbesserung des Fettstoffwechsels wurde als 
Änderung der Lipidparameter erfasst. Die in unserer Studie untersuchten Mechanismen, die 
zu einer Verbesserung des  Glukosestoffwechsels geführt haben, umfassen den Inkretineffekt, 
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die Insulinsensitivität und die ß-Zellfunktion. Der Inkretineffekt wurde als Verbesserung von 
Messwerten (Glukoseinfusionsrate, Insulinkonzentration, C-Peptid-Konzentration) zwischen 
90-120 Minuten (vor der Testmahlzeit) und 125-360 Minuten (nach der Testmahlzeit) 
während des sechsstündigen hyperglykämischen Clamp mit Testmahlzeit festgelegt. Die 
Verbesserung der Insulinsensitivität wurde in Form von Veränderungen des 
Nüchternplasmainsulins, des Nüchternplasma-C-Peptids, des HOMA-IR, der 
Glukoseinfusionsrate während der letzten 60 Minuten des dreistündigen euglykämischen 
Clamps und des Insulinsensitvitätsindex erfasst. Die Veränderungen bezüglich der akute 
Insulin response auf Hyperglykämie (AIRg) und der Disposition Index wurden zur 
Beurteilung der ß-Zell-Funktion herangezogen. 
Ergebnisse 
Zwölf Patienten wurden in die Studie eingeschlossen (8 Frauen, 4 Männer; mittleres Alter 
50,2 ± 2,2 Jahre; mittlere Diabetesdauer 5,2 ± 0,7 Jahre). Die meisten Probanden hatten einen 
gut eingestellten Blutzucker mit einem mittleren HbA1c von 6,7 ± 0,3 % vor dem Beginn der 
kalorischen Restriktion. Die mittlere Energieaufnahme während der ersten Phase und während 
der zweiten Phase der kalorischen Restriktion war 678,8 ± 47,8 kcal/Tag bzw. 1407,3 ± 52,7 
kcal/ Tag.  Der BMI nahm signifikant  von 46,0 ± 2,1 kg/m2 auf 43,8 ± 2.0 kg/m2 (Visit 2, p 
<,001) und 41,7 ± 2,1 kg/m2 (Visit 3, p <,001) ab.  
Eine signifikante Verbesserung des Glukosemetabolismus war sowohl nach der ersten Phase 
als auch nach der zweiten Phase der kalorischen Restriktion feststellbar. Dieser verbesserte 
Glukosestoffwechsel lässt sich  aus der signifikanten Senkung des Nüchternblutzuckers bei 
Visit 2 (Rückgang von 133,1 ± 6,4 mg/dl auf 114,6 ± 6,7 mg/dl, p <,01), und aus der 
kombinierten Senkung des Nüchternblutzuckers, des HbA1c-Werts, und der Dosis von 
antidiabetisch wirksamen Medikamenten bei Visite 3 (Rückgang des Nüchternblutzuckers 
von 133,1 ± 6,4 mg/dl auf 110 ± 4,7 mg/dl, p <,001; Senkung des HbA1c von 6,7 ± 0,3 % auf 
6,2 ± 0,1 %, p = 0,06; Dosisreduktion von Antidiabetika in 5/10 Probanden) ableiten. Auch 
eine signifikante Verbesserung des Fettstoffwechsels war bei Visit 2 und 3 evident 
(Gesamtcholesterin sank signifikant von 182,8 ± 11,9 mg/dl auf 166,4 ± 12,1 mg/dl bzw. 
163,8 ± 11,3 mg/dl , Triglyceride sanken von 127,1 ± 21,5 mg/dl auf 95,3 ± 9,5 mg/dl bzw. 
105,2 ± 12,6 mg/dl; LDL-Cholesterin sank signifikant von 114,2 ± 9,2 mg/dl auf 113,2 ± 11,4 
mg/dl bzw. 103,4 ± 9,0 mg/dl; VLDL-Cholesterin sank von 21,7 ± 4,8 mg/dl auf 14,3 ± 2,0 
mg/dl bzw. 17,6 ± 2,6 mg/dl; VLDL-Triglyceride sanken von 105,5 ± 21,7 mg/dl auf 70,3 ± 
11,6 mg/dl bzw. 90,3 ± 13,4 mg/dl). 
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Die Verbesserung des Glukosestoffwechsels nach kalorischer Restriktion wird in unserer 
Studie vom einem verbesserten Inkretineffekt, einer gesteigerten Insulinsensitivität und einer 
besseren ß-Zell-Funktion begleitet. Die prozentuale Verbesserung des Inkretineffekts von 
Visit 1 bis Visit 3 (nicht eruiert bei Visit 2) war im signifikanten Bereich (von 51,2 ± 5,0 % 
auf 70,6 ± 4,7 %, p <0,05, anhand von Insulindaten ermittelt; von 47,5 ± 4,1 % auf 63,1 ± 4,2 
%, P <0,05, anhand von C-Peptid-Daten ermittelt; von 44,4 ± 6,8 % auf 67,0 ± 3,7 %, p 
<0,01, anhand der Glukoseinfusionsrate ermittelt). Eine verbesserte Insulinsensitivität war nur 
bei Visit 3 feststellbar, nicht jedoch bei Visit 2, und aus der signifikanten Verbesserung des 
Nüchternplasmainsulin (Verringerung von 20,0 ± 2.5 µU/ml auf 9,3 ± 2.5 µU/ml, p <.05), des 
HOMA -IR (Verringerung von 6,7 ± 0,9 auf 2,7 ± 0,8, p <.001), der Glukoseinfusionsrate 
während der letzten 60 Minuten des dreistündigen euglykämischen Clamps (Anstieg von 3,7 
± 0.5 mg/kg/min auf 5,5 ± 0.6 mg/kg / min, p <0,01), und des Insulinsensitivitätsindex 
(Erhöhung von 22,9 ± 3,8 auf 45,5 ± 9,8, p <.05) ableitbar. Eine bessere ß-Zellfunktion war 
aus einer signifikanten Verbesserung der akute Insulin response auf Hyperglykämie bei Visit 
2 ersichtlich (Anstieg der mittleren Differenz der Insulinkonzentrationen im nüchternen 
Zustand und während der ersten zehn Minuten nach dem Glukosebolus während des 
hyperglykämischen Clamps  von 8,4 ± 3.5 µU / ml bei Visit 1 auf 14,5 ± 5.1 µU/ml bei Visit 
2, p <.05). In diesem Zusammenhang stieg auch der Disposition Index bei Visit 3 an (Anstieg 
von 244,2 ± 131,1 bei Visite 1 auf 542,1 ± 201,0 bei Visite 3, p <. 05). Die akute 
Insulinsekretion von ß-Zellen verbesserte sich auch bei Visit 3 und der Disposition Index 
erhöhte sich auch bei Visit 2. Allerdings waren diese Veränderungen nicht signifikant. 
Fazit 
Diese Studie beurteilte die Rolle der kalorischen Restriktion und des Gewichtsverlusts 
bezüglich des Glukose- und Lipidmetabolismus und ermittelte Mechanismen, die hinter einem 
verbesserten Glukosemetabolismus stehen. Die Ergebnisse unserer Studie zeigen, dass 
kalorische Restriktion und Gewichtsverlust zu einer signifikanten Verbesserung des Glukose- 
und Lipidmetabolismus führen. Dieser verbesserte Glukosemetabolismus wird durch einen 
verbesserten Inkretineffekt, eine gesteigerte Insulinsensitivität und eine bessere ß-Zell-
Funktion vermittelt. Allerdings treten diese Verbesserungen zu unterschiedlichen Zeitpunkten 
auf. Während sich die beta-Zellfunktion sehr schnell nach Beginn einer Kalorienrestriktion 
verbessert, kommt es erst im Verlauf von Wochen bis Monaten zu einer Verbesserung der 
Insulinempfindlichkeit. Aufgrund einer Ernährung, die der vergleichbar ist von Patienten, die 
sich einer bariatrischen Operation unterzogen, hatten unsere Probanden auch die gleiche 
durchschnittliche Energieaufnahme und einen ähnlichen Gewichtsverlust wie operierte 
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Patienten. Folglich unterstützen unsere Ergebnisse das Konzept, dass die Verbesserung des 
Glukosemetabolismus nach bariatrischen Operationen zumindest teilweise (wenn nicht ganz) 
durch kalorische Restriktion und Gewichtsreduktion erklärt werden kann. Weitere Studien, in 
welchen der Effekt einer bariatrischen Operation direkt mit diätetischen Maßnahmen 
verglichen wird, sind notwendig, um die positiven Effekte einer Kalorienrestriktion bzw. 
Gewichtsreduktion besser zu verstehen. 
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APPENDICES 
Protocol of hyperglycemic clamp with test meal (Day 1 of visit 1 and visit 3)  
 
actual 
time 
blood 
glucose 
blood 
sample 
Breath 
sample 
VAS 
Circulation notes 
Glucose 
infusion rate 
time  / in duplicate EDTA 13C  RR Puls  D 20% 
min (h:min) (mg/dl) (1,5 ml)   (mmHg) (/min) 
 
(ml/h) 
   √ √ √     
-60 
 /      blood glucose by finger 
stick 
-30 
 /      take blood for adipokines 
2x9ml EDTA+ 2x9 ml serum 
-20 
 / 1     
-15 
  
   
   
-10 
 / 2      
-5 
 / 3      
0 
 / 4  1     
2 
 / 5       
4 
 / 6       
6 
 / 7       
8 
 / 8       
10 
 / 9       
15 
 /        
20 
 / 10       
25 
 /        
30 
 / 11       
35 
 /        
40 
 / 12       
45 
 /        
50 
 / 13       
55 
 /        
60 
 / 14       
65 
 /        
70 
 / 15       
75 
 /        
80 
 / 16       
85 
 /        
90 
 / 17       
95 
 /        
100 
 / 18       
105 
 /   2     
66 
 
110 
 / 19       
115 
 / 20       
120 
 / 21 1 3     
125 
 / 22       
130 
 / 23       
135 
 / 24 2 4     
140 
 / 25       
145 
 / 26       
150 
 / 27 3 5     
155 
 /        
160 
 / 28       
165 
 /  4 6     
170 
 / 29       
175 
 /        
180 
 / 30 5 7     
185 
 /        
190 
 /        
195 
 / 31 6      
200 
 /        
205 
 /        
210 
 / 32 7 8     
215 
 /        
220 
 /        
225 
 / 33 8      
230 
 /        
235 
 /        
240 
 / 34 9 9     
245 
 /        
250 
 /        
255 
 / 35       
260 
 /        
265 
 /        
270 
 / 36 10      
275 
 /        
280 
 /        
285 
 / 37       
290 
 /        
295 
 /        
67 
 
300 
 / 38 11 10     
305 
 /        
310 
 /        
315 
 / 39       
320 
 /        
325 
 /        
330 
 / 40 12      
335 
 /        
340 
 /        
345 
 / 41       
350 
 /        
355 
 /        
360 
 / 42 13 11     
380 
  
   
   
400 
  
   
   
420 
  
   
   
 
 
Protocol of euglycemic clamp (day 2 of visit 1, visit 2, and visit 3) 
 
actual 
time 
blood 
glucose 
blood 
sample 
Glucose 
infusion rate Circulation notes 
time  / in duplicate EDTA D 20% RR Puls  
min (h:min) (mg/dl) (1,5 ml) (ml/h) (mmHg) (/min) . 
-60 
 /     blood glucose by finger stick 
Insertion i.v.-cannula or check if already inserted cannulas are patent 
-50 
  
  
  Take fat tissue biopsie: see page 
10 
-40 
  
  
  
-30 
 / 1     
Start insulin infusion at 1,5 IU/kg BW, Bolus: 
-20 
 /  ml/h   Insulin Bolus:                                  
IU 
-15 
 /  ml/h   Insulin infusion rate:                       
ml/h 
-10 
 /  ml/h   
Start glucose (D20%) infusion 
when blood glucose is <100 mg/dl -5  /  ml/h   
0 
 / 2 ml/h   
5 
 /  ml/h    
10 
 /  ml/h    
15 
 /  ml/h    
68 
 
20 
 / 3 ml/h    
25 
 /  ml/h    
30 
 /  ml/h    
35 
 /  ml/h    
40 
 / 4 ml/h    
45 
 /  ml/h    
50 
 /  ml/h    
55 
 /  ml/h    
60 
 / 5 ml/h    
65 
 /  ml/h    
70 
 /  ml/h    
75 
 /  ml/h    
80 
 / 6 ml/h    
85 
 /  ml/h    
90 
 /  ml/h    
95 
 /  ml/h    
100 
 / 7 ml/h    
105 
 /  ml/h    
110 
 /  ml/h    
 
115 
 /  ml/h    
120 
 / 8 ml/h    
125 
 /  ml/h    
130 
 / 9 ml/h    
135 
 /  ml/h    
140 
 / 10 ml/h    
145 
 /  ml/h    
150 
 / 11 ml/h    
155 
 /  ml/h    
160 
 / 12 ml/h    
165 
 /  ml/h    
170 
 / 13 ml/h    
175 
 /  ml/h    
180 
 / 14 ml/h    
Stop insulin infusion, continue glucose infusion, diabetes lunch 
200 
  
  
   
220 
  
  
   
240 
  
  
   
69 
 
 
 
Protocol of hyperglycemic clamp without test meal (day 3 of visit 1) 
 
actual 
time 
blood 
glucose 
blood 
sample 
 
 Circulation notes 
Glucose 
infusion rate 
time  / in duplicate EDTA   RR Puls  D 20% 
min (h:min) (mg/dl) (1,5 ml)   (mmHg) (/min)  (ml/h) 
   √       
-60 
 /      blood glucose by finger 
stick 
-30 
 /       
-20 
 / 1      
-15 
 /       
-10 
 / 2      
-5 
 / 3      
0 
 / 4       
2 
 / 5       
4 
 / 6       
6 
 / 7       
8 
 / 8       
10 
 / 9       
15 
 /        
20 
 / 10       
25 
 /        
30 
 / 11       
35 
 /        
40 
 / 12       
45 
 /        
50 
 / 13       
55 
 /        
60 
 / 14       
65 
 /        
70 
 / 15       
75 
 /        
80 
 / 16       
85 
 /        
90 
 / 17       
95 
 /        
70 
 
100 
 / 18       
105 
 /        
110 
 / 19       
115 
 /        
120 
 / 20       
125 
 /        
130 
 /        
135 
 /        
140 
 / 21       
145 
 /        
150 
 /        
155 
 /        
160 
 / 22       
165 
 /        
170 
 /        
175 
 /        
180 
 / 23       
185 
 /        
190 
 /        
195 
 /        
200 
 / 24       
205 
 /        
210 
 /        
215 
 /        
220 
 / 25       
225 
 /        
230 
 /        
235 
 /        
240 
 / 26       
245 
 /        
250 
 /        
255 
 /        
260 
 / 27       
265 
 /        
270 
 /        
275 
 /        
280 
 / 28       
285 
 /        
71 
 
290 
 /        
295 
 /        
300 
 / 29       
305 
 /        
310 
 /        
315 
 /        
320 
 / 30       
325 
 /        
330 
 /        
335 
 /        
340 
 / 31       
345 
 /        
350 
 /        
355 
 /        
360 
 / 32       
380 
  
   
   
400 
  
   
   
420 
  
   
   
 
